Results 41 to 50 of about 919,731 (432)

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response

open access: yesFrontiers in Oncology, 2019
Measurable residual disease (MRD) testing after initial chemotherapy treatment can predict relapse and survival in acute myeloid leukemia (AML). However, it has not been established if repeat molecular or genetic testing during chemotherapy can offer ...
Hong Yuen Wong   +16 more
doaj   +1 more source

Macrophage Subsets in Obesity, Aligning the Liver and Adipose Tissue

open access: yesFrontiers in Endocrinology, 2020
The increasing prevalence of obesity is accompanied by a rising incidence in metabolic syndrome and related pathologies such as non-alcoholic fatty liver disease. Macrophages are hypothesized to play central roles in these diseases, through their role as
Anneleen Remmerie   +6 more
doaj   +1 more source

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

open access: yesNew England Journal of Medicine, 2016
BACKGROUND Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice ...
E. Papaemmanuil   +26 more
semanticscholar   +1 more source

Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy

open access: yesFrontiers in Immunology, 2018
Therapeutic approaches that engage immune cells to treat cancer are becoming increasingly utilized in the clinics and demonstrated durable clinical benefit in several solid tumor types.
Emile J. Clappaert   +9 more
doaj   +1 more source

Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms

open access: yesFrontiers in Oncology, 2022
IntroductionCytogenetic analysis is important for stratifying patients with various neoplasms. We explored the use of targeted next generation sequencing (NGS) in detecting chromosomal structural abnormalities or copy number variations (CNVs) in patients
Andrew Ip   +24 more
doaj   +1 more source

Antigen presenting capacity of murine splenic myeloid cells [PDF]

open access: yes, 2017
BACKGROUND: The spleen is an important site for hematopoiesis. It supports development of myeloid cells from bone marrow-derived precursors entering from blood. Myeloid subsets in spleen are not well characterised although dendritic cell (DC) subsets are
Hey, Ying-Ying   +2 more
core   +2 more sources

The mechanics of myeloid cells

open access: yesBiology of the Cell, 2020
AbstractThe effects of cell size, shape and deformability on cellular function have long been a topic of interest. Recently, mechanical phenotyping technologies capable of analysing large numbers of cells in real time have become available. This has important implications for biology and medicine, especially haemato‐oncology and immunology, as immune ...
Mariana J. Kaplan   +8 more
openaire   +6 more sources

Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells

open access: yesNature Communications, 2016
Tissue-resident macrophages are mostly derived from embryonic progenitors. Scott et al. develop a mouse model to specifically deplete Kupffer cells (KC) in vivoand show that monocyte-derived cells can repopulate KC niche and behave similar to their ...
Charlotte L. Scott   +13 more
doaj   +1 more source

Adoptive Transfer of Monocytes Sorted from Bone Marrow

open access: yesBio-Protocol, 2019
Inflammatory Ly6Chi monocytes can give rise to distinct mononuclear myeloid cells in the tumor microenvironment, such as monocytic myeloid-derived suppressor cells (Mo-MDSC), immature macrophages, M2-like tumor-associated macrophages (TAMs), M1-like TAMs
Damya Laoui   +4 more
doaj   +1 more source

Advances in acute myeloid leukemia

open access: yesBritish medical journal, 2021
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
L. Newell, R. Cook
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy